| | |
TABLE OF CONTENTS
| | | | Volume 6, May 2016 | | In this issue Review Original Articles Letters to the Editor Corrigendum | | | | | Advertisement | | Blood Cancer Journal is an online-only, open access journal, publishing high quality research on hematologic malignancies and related disorders.The journal has an Impact Factor of 3.467.
Explore the benefits of submitting your next research article. | | | | | | Review | Top | | The blind men and the AML elephant: can we feel the progress?S Tauro Blood Cancer J 2016 6: e424; 10.1038/bcj.2016.33 Abstract | Full Text | | Original Articles | Top | | Characterization of pediatric Philadelphia-negative B-cell precursor acute lymphoblastic leukemia with kinase fusions in JapanT Imamura, N Kiyokawa, M Kato, C Imai, Y Okamoto, M Yano, K Ohki, Y Yamashita, Y Kodama, A Saito, M Mori, S Ishimaru, T Deguchi, Y Hashii, Y Shimomura, T Hori, K Kato, H Goto, C Ogawa, K Koh, T Taki, A Manabe, A Sato, A Kikuta, S Adachi, K Horibe, A Ohara, A Watanabe, Y Kawano, E Ishii and H Shimada Blood Cancer J 2016 6: e419; 10.1038/bcj.2016.28 Abstract | Full Text | | | | Short-course R-CHOP followed by 90Y-Ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients: 7-year long-term resultsV Stefoni, B Casadei, C Bottelli, G Gaidano, C Ciochetto, M G Cabras, M Ansuinelli, L Argnani, A Broccoli, L Gandolfi, C Pellegrini and P L Zinzani Blood Cancer J 2016 6: e425; 10.1038/bcj.2016.29 Abstract | Full Text | | | | Increased circulating VCAM-1 correlates with advanced disease and poor survival in patients with multiple myeloma: reduction by post-bortezomib and lenalidomide treatmentE Terpos, M Migkou, D Christoulas, M Gavriatopoulou, E Eleutherakis-Papaiakovou, N Kanellias, M Iakovaki, I Panagiotidis, D C Ziogas, D Fotiou, E Kastritis and M A Dimopoulos Blood Cancer J 2016 6: e428; 10.1038/bcj.2016.37 Abstract | Full Text | | Letters to the Editor | Top | | A phase 2 study of bortezomib, cyclophosphamide, pegylated liposomal doxorubicin and dexamethasone for newly diagnosed multiple myelomaP S Becker, T A Gooley, D J Green, N Burwick, T Y Kim, K Kojouri, Y Inoue, D J Moore, E Nelli, T Dennie and W I Bensinger Blood Cancer J 2016 6: e422; 10.1038/bcj.2016.31 Full Text | | | | Busulfan for the treatment of myeloproliferative neoplasms: the Mayo Clinic experienceK Begna, A Abdelatif, S Schwager, C Hanson, A Pardanani and A Tefferi Blood Cancer J 2016 6: e427; 10.1038/bcj.2016.34 Full Text | | | | Differential clinical and prognostic impact of myeloid sarcoma vs medullary myeloid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapyZ Chen, W Wang, J E Cortes, E Liu, R N Miranda, C Zhao, J Yuan, X Lu, W Yang, M D Ameri, H M Kantarjian, L J Medeiros and S Hu Blood Cancer J 2016 6: e418; 10.1038/bcj.2016.27 Full Text | | | | All-trans retinoic acid and interferon-α increase CD38 expression on adult T-cell leukemia cells and sensitize them to T cells bearing anti-CD38 chimeric antigen receptorsK Mihara, T Yoshida, S Ishida, Y Takei, A Kitanaka, K Shimoda, K Morishita, Y Takihara and T Ichinohe Blood Cancer J 2016 6: e421; 10.1038/bcj.2016.30 Full Text | | | | Clinical response to everolimus in a patient with Hodgkin’s lymphoma harboring a TSC2 mutationG F Perini, P V Campregher, J S Ross, S Ali, N Hamerschlak and F P S Santos Blood Cancer J 2016 6: e420; 10.1038/bcj.2016.25 Full Text | | | | Macrolide antibiotics exert antileukemic effects by modulating the autophagic flux through inhibition of hERG1 potassium channelsS Pillozzi, M Masselli, L Gasparoli, M D'Amico, L Polletta, M Veltroni, C Favre, G Basso, A Becchetti and A Arcangeli Blood Cancer J 2016 6: e423; 10.1038/bcj.2016.32 Full Text | | | | The microenvironment of classical Hodgkin lymphoma: heterogeneity by Epstein–Barr virus presence and location within the tumorR Wu, A Sattarzadeh, B Rutgers, A Diepstra, A van den Berg and L Visser Blood Cancer J 2016 6: e417; 10.1038/bcj.2016.26 Full Text | | | | Comparison of intramedullary myeloma and corresponding extramedullary soft tissue plasmacytomas using genetic mutational panel analysesS J de Haart, S M Willems, T Mutis, M J Koudijs, M T van Blokland, H M Lokhorst, R A de Weger and M C Minnema Blood Cancer J 2016 6: e426; 10.1038/bcj.2016.35 Full Text | | Corrigendum | Top | | Molecular correlates of anemia in primary myelofibrosis: a significant and independent association with U2AF1 mutationsD Barraco, Y C Elala, T L Lasho, K H Begna, N Gangat, C Finke, C A Hanson, R P Ketterling, A Pardanani and A Tefferi Blood Cancer J 2016 6: e416; 10.1038/bcj.2016.24 Abstract | Full Text | | | | | Advertisement | | Nature Partner Journals: a new home for your research Over the last two years we have collaborated with over 20 internationally renowned partner organizations to publish cutting-edge open articles in disciplines covering all aspects of research science. Visit our interactive timeline to explore the Nature Partner Journals series and our highlights and milestones so far. | | | | | | You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group |One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2016 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved. | | | | |
No comments:
Post a Comment